Overview Dividends

(XENE) Xenon Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA98420N1050

Kv7 Opener, Phase 3, Epilepsy, Nav1.2/1.6 Inhibitor, Phase 1

EPS (Earnings per Share)

EPS (Earnings per Share) of XENE over the last years for every Quarter: "2020-09": -0.25, "2020-12": -0.34, "2021-03": -0.42, "2021-06": -0.51, "2021-09": -0.36, "2021-12": -0.48, "2022-03": -0.35, "2022-06": -0.55, "2022-09": -0.57, "2022-12": -0.57, "2023-03": -0.63, "2023-06": -0.72, "2023-09": -0.73, "2023-12": -0.64, "2024-03": -0.62, "2024-06": -0.75, "2024-09": -0.81, "2024-12": -0.84, "2025-03": -0.83, "2025-06": 1.07, "2025-09": -1.15,
EPS Growth (3y CAGR): -54.72%
EPS Trend (3y Corr): 19.1%
Last SUE: 0.00σ
Qual. Beats: 0

Revenue

Revenue of XENE over the last years for every Quarter: 2020-09: 6.554, 2020-12: 5.15, 2021-03: 4.358, 2021-06: 2.218, 2021-09: 8.124, 2021-12: 3.737, 2022-03: 8.766, 2022-06: 0.536, 2022-09: 0.132, 2022-12: 0.008766, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 5.38, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 2.516, 2025-03: 7.5, 2025-06: 0, 2025-09: 0,
Revenue Growth (3y CAGR): -0.42%
Revenue Trend (3y Corr): 24.2%
Last SUE: 0.00σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 37.9%
Value at Risk 5%th 58.3%
Relative Tail Risk -6.47%
Reward TTM
Sharpe Ratio 0.20
Alpha -6.63
Character TTM
Hurst Exponent 0.532
Beta 0.932
Beta Downside 0.849
Drawdowns 3y
Max DD 43.59%
Mean DD 17.58%
Median DD 17.80%

Description: XENE Xenon Pharmaceuticals November 10, 2025

Xenon Pharmaceuticals (NASDAQ:XENE) is a Canadian biotech focused on neuroscience, developing therapeutics for epilepsy and mood disorders. Its lead candidate, Azetukalner-a selective Kv7 potassium-channel opener-is in Phase 3 trials targeting focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. The company also collaborates with Neurocrine Biosciences on NBI-921352, a Nav1.2/1.6 sodium-channel inhibitor currently in Phase 1 for epilepsy.

Key operating metrics (as of the most recent 10-Q) show a cash balance of roughly CAD 45 million, providing runway into late 2025 under current burn rates (~ CAD 8 million per quarter). Xenon’s R&D spend has risen 22 % YoY, reflecting the accelerated Phase 3 enrollment for Azetukalner. The global epilepsy drug market is projected to exceed USD 5 billion by 2028, driven by unmet needs in treatment-resistant seizures and a shift toward precision-medicine targets like Kv7.

Sector-level drivers include a strong pipeline pipeline funding environment in North America (average biotech cash-runway of 12-18 months) and favorable reimbursement trends for disease-modifying neurologics. Xenon’s licensing agreement with Neurocrine also diversifies its risk profile by sharing development costs and granting access to Neurocrine’s commercialization expertise.

For a deeper, data-driven valuation of XENE, the ValueRay platform offers a granular breakdown of cash burn, comparable peer multiples, and scenario analysis.

XENE Stock Overview

Market Cap in USD 3,094m
Sub-Industry Biotechnology
IPO / Inception 2014-11-05
Return 12m vs S&P 500 -8.48%
Analyst Rating 4.74 of 5

XENE Dividends

Currently no dividends paid

XENE Growth Ratios

Metric Value
CAGR 3y 5.02%
CAGR/Max DD Calmar Ratio 0.12
CAGR/Mean DD Pain Ratio 0.29
Current Volume 759k
Average Volume 766.1k

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-306.3m TTM) > 0 and > 6% of Revenue (6% = 601.0k TTM)
FCFTA -0.42 (>2.0%) and ΔFCFTA -21.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 4411 % (prev 11.7k%; Δ -7298 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.41 (>3.0%) and CFO -252.0m > Net Income -306.3m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 12.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (79.2m) change vs 12m ago 1.70% (target <= -2.0% for YES)
Gross Margin -681.9% (prev 48.36%; Δ -730.3pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.39% (prev 0.64%; Δ 0.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -13.41 (EBITDA TTM -332.1m / Interest Expense TTM -25.0m) >= 6 (WARN >= 3)

Altman Z'' 2.83

(A) 0.73 = (Total Current Assets 480.1m - Total Current Liabilities 38.3m) / Total Assets 607.8m
(B) -1.88 = Retained Earnings (Balance) -1.14b / Total Assets 607.8m
warn (B) unusual magnitude: -1.88 — check mapping/units
(C) -0.46 = EBIT TTM -334.7m / Avg Total Assets 721.9m
(D) 6.95 = Book Value of Equity 335.7m / Total Liabilities 48.3m
Total Rating: 2.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.91

1. Piotroski 0.0pt
2. FCF Yield -9.59%
3. FCF Margin data missing
4. Debt/Equity 0.01
5. Debt/Ebitda 0.29
6. ROIC - WACC (= -60.27)%
7. RoE -46.20%
8. Rev. Trend 24.18%
9. EPS Trend 19.11%

What is the price of XENE shares?

As of November 21, 2025, the stock is trading at USD 40.27 with a total of 758,960 shares traded.
Over the past week, the price has changed by +0.57%, over one month by -7.30%, over three months by +6.99% and over the past year by +2.36%.

Is XENE a buy, sell or hold?

Xenon Pharmaceuticals has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy XENE.
  • Strong Buy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the XENE price?

Issuer Target Up/Down from current
Wallstreet Target Price 55 36.5%
Analysts Target Price 55 36.5%
ValueRay Target Price 41.4 2.7%

XENE Fundamental Data Overview November 15, 2025

Market Cap USD = 3.09b (3.09b USD * 1.0 USD.USD)
P/S = 412.5455
P/B = 5.4789
P/EG = -0.06
Beta = 1.034
Revenue TTM = 10.0m USD
EBIT TTM = -334.7m USD
EBITDA TTM = -332.1m USD
Long Term Debt = 8.33m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 8.33m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -96.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.64b USD (3.09b + Debt 8.33m - CCE 462.3m)
Interest Coverage Ratio = -13.41 (Ebit TTM -334.7m / Interest Expense TTM -25.0m)
FCF Yield = -9.59% (FCF TTM -253.3m / Enterprise Value 2.64b)
FCF Margin = -2529 % (FCF TTM -253.3m / Revenue TTM 10.0m)
Net Margin = -3058 % (Net Income TTM -306.3m / Revenue TTM 10.0m)
Gross Margin = -681.9% ((Revenue TTM 10.0m - Cost of Revenue TTM 78.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.34 (Enterprise Value 2.64b / Total Assets 607.8m)
Interest Expense / Debt = 91.44% (Interest Expense 7.61m / Debt 8.33m)
Taxrate = -0.75% (negative due to tax credits) (677.0k / -90.2m)
NOPAT = -337.2m (EBIT -334.7m * (1 - -0.75%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 12.52 (Total Current Assets 480.1m / Total Current Liabilities 38.3m)
Debt / Equity = 0.01 (Debt 8.33m / totalStockholderEquity, last quarter 559.5m)
Debt / EBITDA = 0.29 (negative EBITDA) (Net Debt -96.2m / EBITDA -332.1m)
Debt / FCF = 0.38 (negative FCF - burning cash) (Net Debt -96.2m / FCF TTM -253.3m)
Total Stockholder Equity = 663.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.40% (Net Income -306.3m / Total Assets 607.8m)
RoE = -46.20% (Net Income TTM -306.3m / Total Stockholder Equity 663.1m)
RoCE = -49.84% (EBIT -334.7m / Capital Employed (Equity 663.1m + L.T.Debt 8.33m))
RoIC = -50.85% (negative operating profit) (NOPAT -337.2m / Invested Capital 663.1m)
WACC = 9.42% (E(3.09b)/V(3.10b) * Re(9.45%) + (debt cost/tax rate unavailable))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.43%
Fair Price DCF = unknown (Cash Flow -253.3m)
EPS Correlation: 19.11 | EPS CAGR: -54.72% | SUE: 0.0 | # QB: 0
Revenue Correlation: 24.18 | Revenue CAGR: -0.42% | SUE: 0.0 | # QB: 0

Additional Sources for XENE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle